SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dick's Sporting Goods, Inc. engages in the retailing of an extensive assortment of authentic sports equipment, apparel, footwear, and accessories. It also offers its products both online and through mobile applications. The company was founded by Richard T. Stack in 1948 and is headquartered in Coraopolis, PA.

Dicks Sporting Goods, Inc.

DKS is plunging roughly 25% after its Q2 earnings miss and full-year guidance cut, with the community pointing to the struggling Foot Locker acquisition and a promotional athletic apparel market as the main culprits. Traders are debating whether the selloff is an overreaction for dip-buying or signals further downside, with many noting the stock's extreme oversold levels and the weak consumer backdrop.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is plunging after its Q2 report showed strong revenue growth but widened losses and conservative guidance that excludes potential AI project revenue, sparking intense retail debate over dilution fears versus bullish execution optimism.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

LULU is drawing heavy chatter as Michael Burry and BlackRock disclosed fresh buying while the stock gets caught in athletic-retail sympathy selling after Dick's Sporting Goods' weak guidance. Bulls frame it as a deep-value/short-squeeze setup ahead of earnings and the new CEO's start, while bears point to consumer weakness, Canada tariff exposure, and rising Alo/Vuori competition.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical metals names are ripping as speculation over U.S.-China trade tensions and the Western mine-to-magnet push ignites the sector, with CEO Sage's media appearances and Tanbreez progress feeding the bullish frenzy. Traders are buzzing about a potential short squeeze and the upcoming EUR merger, though some still debate the company's published NPV accuracy.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is moving on sympathy with Dick's Sporting Goods' weaker outlook, sparking debate over whether the swoosh is a bargain or a value trap as traders weigh brand struggles, tariffs, and shifting consumer demand.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

The announcement of Navitas' acquisition of Claros to expand its AI data-center power delivery technology is dominating discussion, with the community split between bullish views on the expanded market opportunity and bearish concerns over dilution and the sharp post-announcement price drop.

Greenland Mines Ltd. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Charlotte, NC.

Greenland Mines Ltd.

GRML is trending as traders dissect the post-1-for-50 reverse split landscape, with bulls touting an ultra-low float and a fresh rare earth project valuation while bears warn of looming ATM offering dilution. Community chatter is split between a potential short squeeze and fears of massive dilution from an active equity line, all set against the backdrop of the critical minerals and Greenland geopolitics narrative.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Retail is piling into Immix Biopharma around a heavily shorted float, chatter about a potential squeeze, and anticipation of the upcoming NXC-201 data readout. Traders are also parsing fresh institutional accumulation and lingering CMO-related overhang while debating whether the bullish setup remains intact.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the community reacts to reclaiming the $80K psychological level after a sharp rally, sparking an intense bulls-vs-bears debate over whether the downtrend has broken or a trap is forming. Key talking points include Treasury bond buyback liquidity, a weaker dollar, strong ETF inflows, short squeezes, and whether the bear market is truly over.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending after the FDA accepted a major BLA amendment and extended the PDUFA decision to Nov. 22, sharpening the approval focus on the new upper-limb indication. Community sentiment is polarized between bulls anticipating a de-risked approval and short-squeeze on the heels of the Oppenheimer upgrade, and bears labeling the extension a stalling tactic that merely delays an expected CRL.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Aug. 5, 2026 -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical...

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice

Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Is Q32 Bio Stock Falling Wednesday?

Q32 Bio (QTTB) stock slips after pricing a $200M public offering at $18.25. Get the details on the deal and share reaction.read more...

Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., July 14, 2026 WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc...

$100 Invested In Q32 Bio 5 Years Ago Would Be Worth This Much Today

Q32 Bio (NASDAQ:QTTB) has outperformed the market over the past 5 years by 11.82% on an annualized basis producing an average annual return of 23.91%. Currently, Q32 Bio has a market capitalization of $317.42 million.read more...

Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-market. Other stocks moving lower in pre-market.read more...

Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today? 

Equity

Investors backed strong catalysts, including analyst upgrades, biotech trial results and improving freight outlooks. 


Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Bullish Sentiment

Rallies more than 5%

Modest gain (0-5%)

Modest decline (0-5%)

Drops more than 5%

Nvidia ($NVDA) reports earnings Wednesday, August 26, with options markets pricing in a roughly 5-7% post-earnings move. How do you think Nvidia's stock reacts to earnings? Vote and explain your reasoning in the comments.

Nvidia ($NVDA) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Stocktwits

) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.32	--	--	N/A
Q2 '26	-$0.43	-$0.44	-1.85%	MISSED
Q1 '26	-$0.68	-$0.54	20.59%	BEAT
Q4 '25	-$0.86	$4.58	632.56%	BEAT
Q3 '25	-$1.19	-$0.60	49.58%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings